360 



vorable articles about cigarettes. These articles would then appar- 

 ently be published under the name of the free-lance author with no 

 acknowledgment of the link to the Council. 



For instance, Exhibit 9, a report on tobacco industry research 

 committee information activities contains this entry on page 4, 

 "C.B. Colby, free-lance popularizer of science was retained for re- 

 search and possible writing of articles concerning all the hazards 

 of modern life which people are cautioned against and leading to 

 the conclusion that in spite of all the death scares, you still live 

 longer." 



Is hiring a free-lance popularizer of science urging people to ig- 

 nore death scares a scientific inquiry? 



Mr. Glenn. That is beyond my knowledge, as you must know. I 

 notice this memorandum, however, is an internal memorandum of 

 Hill and Knowlton. They, indeed, are a public relations firm. But 

 they were independent of and separate from the Council for To- 

 bacco Research to my knowledge. 



Mr. Waxman. I dispute that. 



We will move on to other Members who have questions and we 

 will come back to some of these points. 



Mr. Bliley. 



Mr. Bliley. Dr. Glenn, could you identify those who serve on the 

 CTR Scientific Advisory Board, what their background is? 



Mr. Glenn. Yes, sir. Let me go to my notes lest I miss somebody. 

 The Scientific Advisory Board consists of at the present time 15 

 very distinguished individuals; alphabetically they are. Dr. Leo G. 

 Abood, professor of Pharmacology and Biochemistry at the Univer- 

 sity of Rochester; Dr. Barry G. Amison, chairman of the Depart- 

 ment of Urology and director of the Brain Institute at the Univer- 

 sity of Chicago; Dr. Drummond Bouden, chairman of the Depart- 

 ment of Pathology, University of Manitoba; Dr. Michael Brennan, 

 director emeritus of the Michigan Cancer Center in Detroit; Dr. 

 Carl O. Croci, director of the Thomas Jefferson Cancer Center, 

 Thomas Jefferson University, Philadelphia; Dr. Ra3anond Erickson, 

 professor of Molecular Biology, Harvard University; Dr. Joseph 

 Feldman, professor of Immunology and research director emeritus 

 at the Scripps Institute in California; Dr. Gordon Gale, professor 

 of Medicine and Endocrinology at the University of California, San 

 Diego; Dr. W. K. Yaclick, professor and chairman of the Depart- 

 ment of Microbiology at Duke University; Dr. Manfred Camofski, 

 professor of Biochemistry, Harvard University; Dr. Henry Lynch, 

 Creighton University, director of the Department of Preventive 

 Medicine, and the same Lynch to whom I referred previously who 

 is responsible for our most recent understanding of genetic disease 

 for — as the basis for cancer; Dr. Harmon McAllister, a biochemist 

 and our current scientific director, also a member of the board; Dr. 

 Barry Pierce, chairman emeritus of the Department of Pathology, 

 University of Colorado; Dr. Judith Swain, professor of Medicine, di- 

 rector of the Division of Cardiovascular Disease and Medical Genet- 

 ics at the University of Pennsylvania; and Dr. Peter Vote, formerly 

 chairman of the Department of Microbiology at the University of 

 Southern California, now director of research at the Scripps Insti- 

 tute. 



